Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

References

• BeasleyCMJTollefsonGTranPSatterleeWSangerTHamiltonSOlanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trialNeuropsychopharmacology19961421111238822534
   PubMed Web of Science ®Google Scholar
• LindenmayerJPGrochowskiSMabugatLClozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenicsJ Clin Psychopharmacol19941432012048027417
   PubMed Web of Science ®Google Scholar
• BarkicJFilakovicPRadanovic-GrguricLThe influence of risperidone on cognitive functions in schizophreniaColl Antropol200327Suppl 111111812955900
   PubMedGoogle Scholar
• KeefeRSBilderRMDavisSMNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialArch Gen Psychiatry200764663364717548746
   PubMed Web of Science ®Google Scholar
• BuckleyPFGoldsteinJMEmsleyRAEfficacy and tolerability of quetiapine in poorly responsive, chronic schizophreniaSchizophr Res20046623143150
   Web of Science ®Google Scholar
• PeuskensJMollerHJPuechAAmisulpride improves depressive symptoms in acute exacerbations of schizophrenia: Comparison with haloperidol and risperidoneEur Neuropsychopharmacol200212430531012126869
   PubMed Web of Science ®Google Scholar
• ColonnaLSaleemPDondey-NouvelLReinWLong-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study GroupInt Clin Psychopharmacol2000151132210836281
   PubMed Web of Science ®Google Scholar
• SwartzMSPerkinsDOStroupTSEffects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE studyAm J Psychiatry2007164342843617329467
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• MasandPSNarasimhanMImproving adherence to antipsychotic pharmacotherapyCurr Clin Pharmacol200611475618666377
   PubMedGoogle Scholar
• BlackwellBTreatment adherenceBr J Psychiatry1976129513531793670
   PubMed Web of Science ®Google Scholar
• WrightECNon-compliance – or how many aunts has Matilda?Lancet199334288769099138105172
   PubMed Web of Science ®Google Scholar
• WeidenPRapkinBZygmuntAMottTGoldmanDFrancesAPostdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimenPsychiatr Serv19954610104910548829787
   PubMed Web of Science ®Google Scholar
• WeidenPJDiscontinuing and switching antipsychotic medications: Understanding the CATIE schizophrenia trialJ Clin Psychiatry200768Suppl 1121917286523
   PubMed Web of Science ®Google Scholar
• DolderCRLacroJPDunnLBJesteDVAntipsychotic medication adherence: Is there a difference between typical and atypical agents?Am J Psychiatry2002159110310811772697
   PubMed Web of Science ®Google Scholar
• LiebermanJAAlvirJMWoernerMProspective study of psychobiology in first-episode schizophrenia at Hillside HospitalSchizophr Bull19921833513711411327
   PubMed Web of Science ®Google Scholar
• RobinsonDGWoernerMGAlvirJMPredictors of treatment response from a first episode of schizophrenia or schizoaffective disorderAm J Psychiatry1999156454454910200732
   PubMed Web of Science ®Google Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• WiersmaDNienhuisFJSlooffCJGielRNatural course of schizophrenic disorders: A 15-year followup of a Dutch incidence cohortSchizophr Bull199824175859502547
   PubMed Web of Science ®Google Scholar
• LiebermanJAKoreenARChakosMFactors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophreniaJ Clin Psychiatry199657Suppl 9598823344
   PubMed Web of Science ®Google Scholar
• ShepherdMWattDFalloonISmeetonNThe natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenicsPsychol Med Monogr Suppl1989151462798648
   PubMedGoogle Scholar
• MarderSRFacilitating compliance with antipsychotic medicationJ Clin Psychiatry199859Suppl 321259541334
   PubMed Web of Science ®Google Scholar
• MooreASellwoodWStirlingJCompliance and psychological reactance in schizophreniaBr J Clin Psychol200039Pt 328729511033750
   PubMed Web of Science ®Google Scholar
• GilmerTPDolderCRLacroJPAdherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophreniaAm J Psychiatry2004161469269915056516
   PubMed Web of Science ®Google Scholar
• ValensteinMCopelandLABlowFCPharmacy data identify poorly adherent patients with schizophrenia at increased risk for admissionMed Care200240863063912187177
   PubMed Web of Science ®Google Scholar
• MarcusSCOlfsonMOutpatient antipsychotic treatment and inpatient costs of schizophreniaSchizophr Bull200834117318017578893
   PubMed Web of Science ®Google Scholar
• RemingtonGJAdamsMEDepot neuroleptic therapy: Clinical considerationsCan J Psychiatry1995403 Suppl 1S5117627927
   PubMed Web of Science ®Google Scholar
• DavisJMMatalonLWatanabeMDBlakeLMetalonLDepot antipsychotic drugs. Place in therapyDrugs19944757417737520856
   PubMed Web of Science ®Google Scholar
• LehmanAFSteinwachsDMPatterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client SurveySchizophr Bull199824111209502543
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• EdwardsNCLocklearJCRupnowMFDiamondRJCost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USAPharmacoeconomics200523Suppl 1758916416763
   PubMed Web of Science ®Google Scholar
• AnnemansLCost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?Pharmacoeconomics200523Suppl 11216416757
   PubMed Web of Science ®Google Scholar
• TaylorDMFischettiCSparshattAThomasABisharaDCorneliusVRisperidone long-acting injection: A prospective 3-year analysis of its use in clinical practiceJ Clin Psychiatry200970219620019026261
   PubMed Web of Science ®Google Scholar
• LindenmayerJPParakMGormanJMImproved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial responseJ Psychiatr Pract2006121555716432447
   PubMedGoogle Scholar
• PeuskensJOlivaresJMPecenakJTreatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countriesCurr Med Res Opin201026350150920014981
   PubMed Web of Science ®Google Scholar
• HaroJMKamathSAOchoaSThe Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand Suppl2003416162312755850
   PubMedGoogle Scholar
• EndicottJSpitzerRLFleissJLCohenJThe global assessment scale. A procedure for measuring overall severity of psychiatric disturbanceArch Gen Psychiatry1976336766771938196
   PubMed Web of Science ®Google Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioningActa Psychiatr Scand2000101432332910782554
   PubMed Web of Science ®Google Scholar
• FleischhackerWWEerdekensMKarcherKTreatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychoticJ Clin Psychiatry200364101250125714658976
   PubMed Web of Science ®Google Scholar
• KaneJMEerdekensMLindenmayerJPKeithSJLesemMKarcherKLong-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry200316061125113212777271
   PubMed Web of Science ®Google Scholar
• MartinSDLibrettoSEPrattDJBrewinJSHuqZUSalehBTClinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidoneCurr Med Res Opin200319429830512841922
   PubMed Web of Science ®Google Scholar
• LindenmayerJPEerdekensEBerrySAEerdekensMSafety and efficacy of long-acting risperidone in schizophrenia: A 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychoticsJ Clin Psychiatry20046581084108915323593
   PubMed Web of Science ®Google Scholar
• MollerHJLlorcaPMSacchettiEMartinSDMedoriRParelladaEEfficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapiesInt Clin Psychopharmacol200520312113015812261
   PubMed Web of Science ®Google Scholar
• MarinisTDSaleemPTGluePSwitching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophreniaPharmacopsychiatry200740625726318030649
   PubMed Web of Science ®Google Scholar
• TurnerMEerdekensEJackoMEerdekensMLong-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychoticsInt Clin Psychopharmacol200419424124915201572
   PubMed Web of Science ®Google Scholar
• SchmaussMSacchettiEKahnJPMedoriREfficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidoneInt Clin Psychopharmacol2007222859217293708
   PubMed Web of Science ®Google Scholar
• MasandPSRocaMTurnerMSKaneJMPartial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A reviewPrim Care Companion J Clin Psychiatry200911414715419750066
   PubMedGoogle Scholar
• FleischhackerWWOehlMAHummerMFactors influencing compliance in schizophrenia patientsJ Clin Psychiatry200364Suppl 16101314680413
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• RosaMAMarcolinMAElkisHEvaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophreniaRev Bras Psiquiatr200527317818416224604
   PubMed Web of Science ®Google Scholar
• BebbingtonPEThe content and context of complianceInt Clin Psychopharmacol19959Suppl 541507622833
   PubMed Web of Science ®Google Scholar
• ChuePLong-acting risperidone injection: Efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychoticNeuropsychiatr Dis Treat200731133919300536
   PubMedGoogle Scholar
• PatelMXde ZoysaNBernadtMDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: Depot versus oralJ Clin Psychiatry200869101548155619192437
   PubMed Web of Science ®Google Scholar
• NasrallahHATargumSDTandonRMcCombsJSRossRDefining and measuring clinical effectiveness in the treatment of schizophreniaPsychiatr Serv200556327328215746501
   PubMed Web of Science ®Google Scholar
• FleischhackerWWRabinowitzJKemmlerGEerdekensMMehnertAPerceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 yearBr J Psychiatry200518713113616055823
   PubMed Web of Science ®Google Scholar
• NasrallahHADuchesneIMehnertAJanagapCEerdekensMHealth-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidoneJ Clin Psychiatry200465453153615119916
   PubMed Web of Science ®Google Scholar
• AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: Costs, clinical outcomes and quality of lifeBr J Psychiatry200418434635115056580
   PubMed Web of Science ®Google Scholar
• GoereeRFarahatiFBurkeNThe economic burden of schizophrenia in Canada in 2004Curr Med Res Opin200521122017202816368053
   PubMed Web of Science ®Google Scholar
• VehofJPostmaMJBruggemanRPredictors for starting depot administration of risperidone in chronic users of antipsychoticsJ Clin Psychopharmacol200828662563019011430
   PubMed Web of Science ®Google Scholar
• EmsleyRMedoriRKoenLOosthuizenPPNiehausDJRabinowitzJLong-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary studyJ Clin Psychopharmacol200828221021318344732
   PubMed Web of Science ®Google Scholar
• EmsleyROosthuizenPKoenLNiehausDJMedoriRRabinowitzJRemission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injectionInt Clin Psychopharmacol200823632533118854720
   PubMed Web of Science ®Google Scholar
• ParelladaEAndrezinaRMilanovaVPatients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectableJ Psychopharmacol200519Suppl 551416144781
   PubMed Web of Science ®Google Scholar
• LambertTBrennanACastleDKellyDLConleyRRPerception of depot antipsychotics by mental health professionalsJ Psychiatr Pract20039325226015985940
   PubMedGoogle Scholar
• PereiraSPintoRA survey of the attitudes of chronic psychiatric patients living in the community toward their medicationActa Psychiatr Scand19979564644689242840
   PubMed Web of Science ®Google Scholar